source
- FDA sets May 1 decision deadline for UniQure’s Huntington’s disease gene therapy after advisory committee meetingThe U.S. Food and Drug Administration announced that it has set a review date and scheduled an advisory committee meeting for UniQure’s gene therapy aimed at treating Huntington’s disease. The age…
- FDA places Bright Minds seizure drug BMB-101 on partial hold over mouse toxicity, shares plungeThe U.S. Food and Drug Administration issued a partial clinical hold on BMB-101, an experimental seizure treatment from Bright Minds Biosciences, after regulators identified toxicity concerns in pr…